Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE).

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-05-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painpostchestresectionchronic
  Phrases that lowered it: allergylungadultsdisorderspregnant
• Sponsor's past termination rate: 2.6% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 42 (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 68.3% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 92627 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 19337 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Keywords listed: 6 (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy NCT01116583 · started 2011 · scored riskier than 43% of active trials completed
• Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy NCT05172570 · started 2021 · scored riskier than 73% of active trials terminated
• Gabapentin as Adjunctive Treatment for Postoperative Pain Control NCT02490345 · started 2015 · scored riskier than 37% of active trials completed
• Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain NCT02678117 · started 2015 · scored riskier than 7% of active trials completed
• Effect of Gabapentin on Postoperative Morphine Consumption After Sleeve Gastrectomy NCT03023501 · started 2014 · scored riskier than 57% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.